Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.
Shan ChongPeng ZhaoRui-Bin HuangHu ZhouJia-Ning ZhangMing HouYi LiuHong-Xia YaoTing NiuJun PengMing JiangYan-Qiu HanJian-Da HuZe-Ping ZhouLin QiuLian-Sheng ZhangXin WangHua-Quan WangRu FengLin-Hua YangLiang-Ming MaShun-Qing WangPei-Yan KongWen-Sheng WangHui-Ping SunJing SunHe-Bing ZhouTie-Nan ZhuLi-Ru WangJing-Yu ZhangQiu-Sha HuangHai-Xia FuYe-Jun WuYue-Ying LiQian-Fei WangQian JiangHao JiangJin LuXiao-Jun HuangXiao-Hui ZhangPublished in: Blood advances (2022)
Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide multicenter real-world study of ICH in adult ITP patients. According to data from 27 centers in China from 2005 to 2020, the mortality rate from ICH was 33.80% (48/142) in ITP adults. We identified risk factors by logistic univariate and multivariate logistic regression for 30-day mortality in a training cohort of 107 patients as follows: intraparenchymal hemorrhage (IPH), platelet count ≤10 × 109/L at ICH, a combination of serious infections, grade of preceding bleeding events, and Glasgow coma scale (GCS) level on admission. Accordingly, a prognostic model of 30-day mortality was developed based on the regression equation. Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a test cohort with 35 patients from 11 other centers was conducted. The areas under the receiver operating characteristic (ROC) curves for the internal and external validation were 0.954 (95% confidence interval [CI], 0.910-0.998) and 0.942 (95% CI, 0.871-1.014), respectively. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.